Themis Bioscience and the Coalition for Epidemic Preparedness Innovations (CEPI) have entered a partnership under which Themis will provide advanced vaccine development and manufacturing for Lassa fever and MERS. This is the first company agreement that CEPI has signed since it was established in 2017 as a coalition to finance and coordinate the development of new vaccines to prevent and contain infectious disease epidemics.   The investment of up to $37.5 million represents an in...